Speed of Action: Bypassing the digestive system means a faster onset of systemic action
However, there are plausible reasons why some patients might experience musculoskeletal pain while using GLP-1 receptor agonists
No rule change has been finalized as of mid-2026, but this is a conversation worth tracking if you are struggling with early compliance
Because each of the major studies for SGLT2is, GLP1-RAs, and nsMRAs added these newer therapies to participants on the maximum label or tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), it is suggested that cardiorenal protective therapy begin with either an ACEi or an ARB, titrated to either the label maximum or the maximum tolerated dose (see Table 1 for list of currently approved ACEi and ARB in Canada and the maximally recommended dosing)
It pushed us toward a more science-informed culinary model, which I believe is the future of hospitality. Science does play an important role in understanding the GLP-1 consumer
Share your interest in natural remedies for hyperthyroidism at your next visit
